Metabolic Dysfunction Associated Steatotic Liver Disease clinical trials

Explore recruiting metabolic dysfunction associated steatotic liver disease clinical trials.

Recruiting metabolic dysfunction associated steatotic liver disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metabolic Dysfunction Associated Steatotic Liver Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Czechia, France, Netherlands, Bulgaria, Norway, Austria +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

First-in-human (FIH), microdosing, non-randomized, clinical trial to investigate binding of positron emission tomography tracer [68Ga]Ga-DOTA-Cys-ATH001 targeting platelet derived growth factor receptor β in healthy subjects as compared to patients with metabolic dysfunction-associated steatohepatitis (MASH) and Primary Sclerosing Cholangitis binding (PSC, liver) and patients with fibrostenotic Crohn’s disease (CD, gastrointestinal tract [GI])

Sweden

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Spain, Poland, France, Italy, Bulgaria, Belgium +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Impact of Glucagon on Physical Capacity and Metabolism

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Clinical Trial of Tirzepatide (LY3298176) in Subjects With Overweight or Obesity and PCOS-related Ovarian Dysfunction (PERIODS)

Germany

Therapeutic use (Phase IV) EU CTIS Study details

ADVANCE: A Phase III Multi-Centre, Randomised, Double-Blind, Double-Dummy Clinical Trial Comparing Essentiale® Liquid vs. Capsules for MASLD/MASH, Alcoholic Liver Disease, and Chronic Viral Hepatitis B

Bulgaria, Germany, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Metabolic Dysfunction Associated Steatotic Liver Disease trials by city

Metabolic Dysfunction Associated Steatotic Liver Disease in Toronto Metabolic Dysfunction Associated Steatotic Liver Disease in Vancouver Metabolic Dysfunction Associated Steatotic Liver Disease in Montreal Metabolic Dysfunction Associated Steatotic Liver Disease in Calgary Metabolic Dysfunction Associated Steatotic Liver Disease in Edmonton Metabolic Dysfunction Associated Steatotic Liver Disease in Ottawa Metabolic Dysfunction Associated Steatotic Liver Disease in Winnipeg Metabolic Dysfunction Associated Steatotic Liver Disease in Quebec City Metabolic Dysfunction Associated Steatotic Liver Disease in Hamilton Metabolic Dysfunction Associated Steatotic Liver Disease in Kitchener Metabolic Dysfunction Associated Steatotic Liver Disease in London Metabolic Dysfunction Associated Steatotic Liver Disease in Halifax Metabolic Dysfunction Associated Steatotic Liver Disease in New York Metabolic Dysfunction Associated Steatotic Liver Disease in Los Angeles Metabolic Dysfunction Associated Steatotic Liver Disease in Chicago Metabolic Dysfunction Associated Steatotic Liver Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease